asp3652
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT02243657)
Timeline
Indications
Mechanism of action
- Anandamide amidohydrolaseINHIBITOR
FAAH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- asp3652
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02034734 | Phase 1 | Sep 1, 2012 | Astellas |
| NCT01815684 | Phase 1 | Aug 1, 2012 | Astellas |
| NCT02046798 | Phase 1 | Jul 1, 2012 | Astellas |
| NCT01958047 | Phase 1 | Jul 1, 2012 | Astellas |
| NCT01613586 | Phase 2 | May 1, 2012 | Astellas |
| NCT01797198 | Phase 1 | Apr 1, 2012 | Astellas |
| NCT01391338 | Phase 2 | Jun 1, 2011 | Astellas |
| NCT02243657 | Phase 1 | May 1, 2009 | Astellas |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 8 | 8 | 2 | 2009 |
1 organizations
Page 1 / 1